Solventum (SOLV) Q4 2025 Adjusted Diluted EPS Reaches $1.57 on 3.5% Organic Sales Growth [Yahoo! Finance]
HLS Therapeutics Announces NILEMDOTM (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of Cardiovascular Disease [Globe and Mail, The (Toronto, Canada)]
Esperion Therapeutics Inc (ESPR) Strengthens Business Outlook Amid Strategic Agreements [Yahoo! Finance]
Esperion Therapeutics, Inc. (ESPR) M&A Call Transcript [Seeking Alpha]
Esperion Therapeutics (ESPR) had its price target raised by Needham & Company LLC from $4.00 to $5.00. They now have a "buy" rating on the stock.